


# HOMBURGER AND NKF ON VECTIVBIO IPO ON NASDAQ

*Posted on 14 April 2021*



**Categories:** [Capital Markets](#), [Diversity and Inclusion](#)

**Tags:** [Andreas Müller](#), [Homburger](#), [News](#)



VectivBio Holding AG announced its initial public offering and listing of its shares on Nasdaq (ticker symbol VECT). VectivBio is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. Through its IPO, at USD 17 per share, VectivBio raises gross proceeds of USD 146.6 m (including greenshoe). At market close on the first day of trading, VectivBio had a market capitalization of USD 824 m.

Homburger advises VectivBio Holding AG in this matter with a team including partner **Andreas Müller** (Capital Markets; Corporate / M&A; Employment and Executive Compensation), lead associate **Margrit Marti**, associates **Angela Oppliger** and **Kevin Hubacher** and junior associate **Daniel Bötticher** (all Capital Markets; Corporate / M&A), partner **Stefan Oesterhelt** and associates **Joël Gyger** and **Raphaël Fellay** (all Tax), and partner **Luca Dal Molin** (IP/IT).

Niederer Kraft Frey advised the banking syndicate, led by BofA Securities, SVB Leerink and Credit



Suisse with a team led by Capital Markets partners **Thomas Brönnimann** and **Philippe Weber** (pictured left), working with senior associate **Deirdre Ni Annrachain** (Capital Markets), partner **Markus Kronauer** and associate **Vanessa Witschi** (both Tax).